ArticleAmerican journal of nephrology2016
Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency Cohort Study.
Article in American journal of nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Genome-wide meta-analysis identifies new candidate genes for sickle cell disease nephropathy.Blood advances · 2023Pooled it
- 1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2018Trial
- FIA-MS/MS-Based Targeted Metabolomics of Amino Acids and Acylcarnitines Uncovers Network-Level Metabolic Reprogramming in Chronic Kidney Disease.Biomedicines · 2026Article
- Serum Metabolomic Profiling Reveals Distinct Signatures and Candidate Biomarkers in Chronic Kidney Disease.International journal of nephrology and renovascular disease · 2026Article
- Integrative multi-omics profiling for early diagnosis, stratification and personalized management of chronic kidney disease: a new paradigm.Clinical and experimental medicine · 2025Review
- Femoral arteriovenous concentration differences reveal metabolomic shifts in peripheral artery disease (PAD): A case-control study.Vascular medicine (London, England) · 2025Article
- Serum amino acid alterations in hyperuricemia: potential targets for renal disease prevention.Amino acids · 2025Article
- Study on Predictive Models for Differential Diagnosis of Diabetic Kidney Disease and Non-Diabetic Kidney Disease Based on Clinical and Biochemical Indicators.International journal of medical sciences · 2025Article
- Frailty and sarcopenia metabolomic signatures in kidney transplant candidates: the FRAILMar study.Clinical kidney journal · 2025Article
- Associations between Kidney Disease Progression and Metabolomic Profiling in Stable Kidney Transplant Recipients-A 3 Year Follow-Up Prospective Study.Journal of clinical medicine · 2024Article
- Exposome and Metabolome Analysis of Sugarcane Workers Reveals Predictors of Kidney Injury.Kidney international reports · 2024Article
- Metabolic implications of amino acid metabolites in chronic kidney disease progression: a metabolomics analysis using OPLS-DA and MBRole2.0 database.International urology and nephrology · 2024Article
- Plasma Metabolomics of Dietary Intake of Protein-Rich Foods and Kidney Disease Progression in Children.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2024Article
- Serum and urine metabolomic biomarkers for predicting prognosis in patients with immunoglobulin A nephropathy.Kidney research and clinical practice · 2023Article
- A Metabolomics study of metabolites associated with the glomerular filtration rate.BMC nephrology · 2023Article
- Causal effects of human serum metabolites on occurrence and progress indicators of chronic kidney disease: a two-sample Mendelian randomization study.Frontiers in nutrition · 2023Article
- Metabolic profiling identifies the significance of caffeine metabolism in CKD.Frontiers in bioengineering and biotechnology · 2023Article
- Metabolic flux between organs measured by arteriovenous metabolite gradients.Experimental & molecular medicine · 2022Review
- Metabolomics of Arterial Stiffness.Metabolites · 2022Review
- Toxicometabolomics and Biotransformation Product Elucidation in Single Zebrafish Embryos Exposed to Carbamazepine from Environmentally-Relevant to Morphologically Altering Doses.Chemical research in toxicology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundWhereas several longitudinal metabolomics studies have been conducted in individuals with normal estimated glomerular filtration rate (eGFR) at baseline, disease progression among individuals with established chronic kidney disease (CKD) has not been rigorously examined.
methodsWe performed a nested case-control study of rapid CKD progression in the Chronic Renal Insufficiency Cohort Study, profiling baseline plasma from 200 individuals each with eGFR slope <-3 ml/min/1.73 m2/year (cases) or between -1 and +1 ml/min/1.73 m2/year (controls), matched on baseline eGFR and proteinuria. To directly assess how the kidney modulates circulating metabolites, we profiled plasma from the aorta and renal vein of 25 hospital-based individuals.
resultsAt baseline, cases and controls had a mean eGFR of 41.7 ± 13.3 and 45.0 ± 14.5 ml/min/1.73 m2, respectively. Ten plasma metabolites were nominally associated with CKD progression in logistic regression models adjusted for age, sex, race/ethnicity, hypertension, systolic and diastolic blood pressure, diabetes, eGFR and proteinuria; no metabolite achieved the Bonferroni-adjusted significance threshold (p < 0.0003). In a cross-sectional analysis, all 6 of the metabolites that were higher in cases than controls were significantly associated with eGFR at baseline. By contrast, threonine, methionine and arginine were lower in cases than in controls and had no association with baseline eGFR. Furthermore, in the hospital-based cohort that underwent renal arteriovenous sampling, these 3 metabolites were net released from the kidney. Combining these metabolites into a panel of markers further strengthened their association with CKD progression.
conclusionOur results motivate interest in arginine, methionine and threonine as potential indicators of renal metabolic function and markers of renal prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.